The approval of the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel provides another treatment option for some patients with relapsed/refractory multiple myeloma. Review this expert commentary on how to incorporate this therapeutic agent into your practice.
CAR T-cell therapies can meaningfully improve outcomes for patients with certain hematologic cancers, but these treatments can cause a unique spectrum of adverse events to which physicians must be attuned. In this commentary, an expert describes key considerations in managing delayed toxicities associated with CAR T-cell therapy, including cytopenias and infections.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.